Anti-Mouse Ly-6G [Clone 1A8] — Purified in vivo GOLD™ Functional Grade

The clone 1A8, specifically targeting the mouse Ly-6G marker, is widely used in several in vivo applications in mice. Here are some of the common applications:

1. Neutrophil Depletion: Clone 1A8 is extensively used for in vivo neutrophil depletion in mice. It specifically targets Ly-6G, a marker exclusive to neutrophils, making it a crucial tool for studying the role of neutrophils in various disease models and biological processes.

2. Immune Response Studies: By depleting neutrophils, researchers can investigate the immune response in contexts such as infectious diseases and inflammation.

3. Cancer Research: Clone 1A8 is utilized in cancer studies to explore the role of neutrophils in cancer progression and immunotherapy.

4. Inflammation Studies: The antibody helps in understanding the role of neutrophils in inflammatory processes, which is beneficial for studying conditions like autoimmune diseases and wound healing.

In addition to in vivo applications, clone 1A8 is also used in various in vitro techniques such as flow cytometry, immunohistochemistry, and immunofluorescence for analyzing neutrophil populations.

Commonly used antibodies or proteins alongside 1A8 (anti-Ly6G, a neutrophil marker) in the literature include those targeting cell lineage and immune subset markers, particularly in flow cytometry and immunohistochemistry studies.

Key antibodies frequently used with 1A8:

• CD45: Pan-leukocyte marker (helps to gate all leukocytes for population analysis).
• CD11b: Myeloid cell marker (identifies myeloid lineage cells such as monocytes, macrophages, and neutrophils).
• F4/80: Macrophage marker (used to distinguish macrophages from neutrophils and other myeloid cells).
• Ly6C: Monocyte subset marker (distinguishes monocytes and some T-cell subsets; used to avoid overlap with Ly6G and to separate neutrophils from monocytes).
• RB6-8C5 (anti-Ly6G/Ly6C): Sometimes used for comparison as it recognizes both Ly6G and Ly6C and thus also depletes monocytes; helps demonstrate specificity of 1A8 for neutrophils in depletion experiments.
• CD101, CXCR2, CXCR4: Used in combination in certain tumor models to assess neutrophil maturity.
• Isotype controls (rat IgG2a): Crucial for background and nonspecific binding control in both in vivo and in vitro applications.

In summary, CD45, CD11b, F4/80, and Ly6C are the most commonly used antibodies with 1A8, especially in flow cytometric analysis to precisely identify and separate neutrophils from other myeloid and immune cell subsets. This panel allows researchers to:

• Exclude or include myeloid populations,
• Distinguish neutrophils from monocytes/macrophages,
• Accurately quantify neutrophil depletion or presence.

RB6-8C5 is used primarily as a reference or for cross-validation of depletion efficacy because it also targets Ly6C, affecting additional cell types. Additional markers such as CD101, CXCR2, and CXCR4 are chosen for more specialized functional or maturity studies.

These combinations provide comprehensive immune profiling alongside 1A8, ensuring high specificity and accuracy in both depletion and identification studies.

Clone 1A8 is widely cited in scientific literature as a monoclonal antibody that specifically targets mouse Ly6G, enabling depletion of neutrophils for functional studies in vivo. Key findings from 1A8 citations highlight its critical role in uncovering neutrophil functions in immunity, disease models, and optimizing depletion protocols.

Essential context and key insights:

• Specificity for Neutrophil Depletion: 1A8 recognizes Ly6G, a surface antigen uniquely expressed by neutrophils, allowing it to deplete this cell population without affecting other leukocytes—unlike antibodies such as RB6-8C5, which target Gr-1 and can impact monocytes as well.
• Functional Impact on Immune Response: Neutrophil depletion using 1A8 has revealed their previously underappreciated importance in pathogen clearance (including Listeria monocytogenes), showing that loss of neutrophils impairs bacterial defense and modifies inflammatory responses.
• Disease Models: In acute inflammation (e.g., zymosan-induced peritonitis), 1A8 treatment demonstrated that neutrophils are pivotal for the initial phase of response and tissue repair. Studies using 1A8 have shown that depletion dramatically worsens outcomes in conditions requiring neutrophil activity, such as bacterial sepsis, underscoring their protective role.
• Protocol Optimization: Standard depletion regimens involve doses ranging from 100–500 μg, typically administered one day before experimental challenge; most protocols recommend adjusting for mouse strain, disease model, and duration needed, but not radically altering these parameters. Murinized variants (mouse IgG2a isotype) of 1A8 enable long-term depletion (up to four weeks), allowing studies in immune-deficient and tumor-bearing mouse models.
• Preclinical Research Applications: 1A8 is commonly used in preclinical studies to model neutropenia, examine neutrophil-dependent pathology, and dissect their role in chronic inflammation and cancer progression.

Additional supporting details:

• 1A8 can be used for flow cytometry and immunohistochemistry to detect or quantify neutrophils in mouse tissues in addition to depletion.
• Its specificity minimizes confounding off-target effects when interpreting immune responses or disease outcomes.
• The antibody is recommended for use in sterile environments and must be titrated carefully for optimal depletion or detection.

Summary Table: Clone 1A8 Key Findings

These findings have made clone 1A8 a standard tool in immunology for dissecting the roles of neutrophils in host defense, inflammation, and disease mechanisms.

Variability in 1A8 (Anti-Ly6G) Dosing Regimens Across Mouse Models

Summary
The dosing regimen for clone 1A8 (anti-Ly6G), used for neutrophil depletion in mice, generally follows a typical range of 100–250 µg per mouse, administered intraperitoneally (i.p.) three times per week. However, this regimen can vary depending on mouse strain, age, experimental model, and specific research objectives.

Key Variables Affecting 1A8 Dosing

Strain and Age
Efficacy of 1A8-induced neutrophil depletion can differ by mouse strain and age. For example, while 1A8 effectively depletes neutrophils in young BALB/c, FVB/N, and C57BL/6J mice, it may be less effective in older C57BL/6J mice or in certain infection models. Some studies have also shown differential depletion efficiency in bone marrow neutrophils depending on the strain.

Experimental Context
The nature of the study—acute versus chronic, infection versus tumor—can influence the optimal dose and frequency. For long-term or more durable depletion, some protocols may require higher or more frequent dosing, or even combination with secondary antibodies to achieve deeper depletion.

Dose Range and Administration Route

• Standard dose: 100–250 µg per mouse, i.p.
• Frequency: Typically every 2–3 days (three times per week)
• Alternative dosing: Some protocols use a single high dose (e.g., two doses of 100 µg i.v. in PBS for acute depletion).
• Per kg dosing: Reported as 7.5–20 mg/kg, but this is less common in the literature for clone 1A8 compared to per mouse dosing.

Specific Examples from the Literature

• General depletion: Most studies use 100–250 µg/mouse i.p. every 2–3 days for neutrophil depletion in standard models (e.g., tumor, inflammation).
• Acute models: A study depleted neutrophils in recipient mice with two doses of 100 µg 1A8 i.v. in 100 µL PBS.
• Long-term depletion: In a study targeting older mice, three weekly injections of 50–100 µg were tested, suggesting that lower or less frequent dosing may be sufficient in some contexts, but efficacy must be validated.
• Strain-specific differences: C57BL/6J mice, especially older ones, may require higher or more frequent doses, or alternative strategies (e.g., secondary antibody) to achieve significant depletion.
• Efficacy limitations: 1A8 may be less effective at depleting immature neutrophils, and complete depletion is not always achieved, particularly in certain tumor or infection models.

Recommendations for Protocol Optimization

• Validate depletion: Always confirm neutrophil depletion efficiency in your specific model using flow cytometry, especially when using a new strain, age group, or disease context.
• Consider isotype controls: Include appropriate isotype controls to rule out non-specific effects.
• Adjust for experimental needs: For acute studies, higher or more frequent dosing may be necessary; for chronic studies, consider the impact of repeated dosing on animal health and experimental outcomes.
• Consult manufacturer guidelines: Refer to product datasheets and peer-reviewed protocols for strain- and model-specific recommendations.

Table: Typical 1A8 Dosing Regimens in Mouse Models

Conclusion

While the standard 1A8 dosing regimen is 100–250 µg per mouse i.p. three times per week, significant variability exists based on mouse strain, age, experimental model, and desired depth of depletion. Researchers must tailor the regimen to their specific context and rigorously validate depletion efficiency, especially when working with non-standard strains, older mice, or complex disease models. Always consult recent literature and product guidelines to optimize the protocol for your study.